We are live on
!
Find out more
IHM
Iguana Healthcare Management Portfolio holdings
AUM
$152M
1-Year Est. Return
48.74%
This Fund
S&P 500
This Quarter
Est. Return
+23.92%
1 Year Est. Return
+48.74%
3 Year Est. Return
+142.13%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$238M
AUM Growth
+$30.8M
(+15%)
Cap. Flow
+$7.19M
Cap. Flow
% of AUM
3.03%
Top 10 Holdings %
Top 10 Hldgs %
44.18%
Holding
90
New
31
Increased
11
Reduced
13
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$17.6M |
| 2 |
AGN
Allergan plc
AGN
|
+$7.13M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
+$6.94M |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$6.03M |
| 5 |
ESRX
Express Scripts Holding Company
ESRX
|
+$5.03M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$13.6M |
| 2 |
Medtronic
MDT
|
+$9.03M |
| 3 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$6.13M |
| 4 |
Viatris
VTRS
|
+$5.64M |
| 5 |
Amgen
AMGN
|
+$5.58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.93% |
| 2 | Real Estate | 0.91% |
| 3 | Technology | 0.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FLXN
51
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $1.13M | 0.47% |
50,000
-25,000
| -33% | -$579K |
|
52
Haemonetics
HAE
$4.16B
| $1.12M | 0.47% |
+25,000
| New | +$1.05M |
|
53
Nektar Therapeutics
NKTR
$2.57B
| $1.1M | 0.46% |
+6,667
| New | +$1.37M |
|
|
DBVT
54
DBV Technologies
DBVT
$885M
| $1.05M | 0.44% |
+4,500
| New | +$1.07M |
|
55
Pacific Biosciences
PACB
$345M
| $876K | 0.37% |
+150,000
| New | +$1.03M |
|
|
ELGX
56
DELISTED
Endologix Inc
ELGX
| $854K | 0.36% |
5,000
+2,500
| +100% | +$379K |
|
57
OraSure Technologies
OSUR
$259M
| $687K | 0.29% |
105,000
-95,000
| -48% | -$789K |
|
|
TSRO
58
DELISTED
TESARO, Inc.
TSRO
| $574K | 0.24% |
+10,000
| New | +$471K |
|
|
ASRT
59
DELISTED
Assertio
ASRT
| $560K | 0.24% |
+417
| New | +$513K |
|
|
TLOG
60
DELISTED
TetraLogic Pharmaceuticals Corporation
TLOG
| $438K | 0.18% |
+100,000
| New | +$502K |
|
|
LITS
61
Lite Strategy Inc
LITS
$31M
| $269K | 0.11% |
7,500
-5,000
| -40% | -$448K |
|
|
IMMU
62
DELISTED
Immunomedics Inc
IMMU
| $192K | 0.08% |
+50,000
| New | +$217K |
|
63
Alkermes
ALKS
$8.44B
| – | – |
-50,000
| Closed | -$2.93M |
|
|
64
Amgen
AMGN
$225B
| – | – |
-35,000
| Closed | -$5.58M |
|
65
BioCryst Pharmaceuticals
BCRX
$2.71B
| – | – |
-75,000
| Closed | -$912K |
|
|
66
Biogen
BIIB
$30.9B
| – | – |
-40,000
| Closed | -$13.6M |
|
|
67
PUT
Biogen
BIIB
$30.9B
| – | – |
-10,000
| Closed | -$3.4M |
|
|
68
CALL
Medtronic
MDT
$116B
| – | – |
-25,000
| Closed | -$1.8M |
|
|
69
Medtronic
MDT
$116B
| – | – |
-125,000
| Closed | -$9.03M |
|
|
LITS
70
CALL
Lite Strategy Inc
LITS
$31M
| – | – |
-5,000
| Closed | -$427K |
|
|
71
CALL
Nektar Therapeutics
NKTR
$2.57B
| – | – |
-3,333
| Closed | -$775K |
|
72
CALL
QuidelOrtho
QDEL
$1.02B
| – | – |
-10,000
| Closed | -$289K |
|
|
73
QuidelOrtho
QDEL
$1.02B
| – | – |
-75,000
| Closed | -$2.17M |
|
74
Sanofi
SNY
$105B
| – | – |
-100,000
| Closed | -$4.56M |
|
75
Tenet Healthcare
THC
$21.5B
| – | – |
-75,000
| Closed | -$3.8M |
|
Similar funds
HWP
PAM
USG2
LCM
FPF
FIAS
CII
OPWM
Iguana Healthcare Management's Q1 2015 Portfolio in Review
As of Q1 2015, Iguana Healthcare Management held 90 positions worth $238M, up 15% from $207M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Iguana Healthcare Management deployed $7.19M of net new capital in Q1 2015, opening 31 new positions and adding to 11 existing holdings. Its largest new stake was Allergan plc: 25,000 shares worth $7.44M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 71% a quarter earlier, followed by Real Estate and Technology.
On the sell side, the largest reduction was Gilead Sciences, an estimated $2.54M trimmed.
- Iguana Healthcare Management's largest Q1 2015 buy was Allergan plc: 25,000 shares worth $7.44M.
- Iguana Healthcare Management added most to Pfizer in Q1 2015, an estimated $17.6M increase.
- Iguana Healthcare Management's biggest Q1 2015 reduction was Gilead Sciences, cutting an estimated $2.54M.
- Iguana Healthcare Management fully exited Biogen in Q1 2015, selling an estimated $13.6M.
- Iguana Healthcare Management's ten largest holdings make up 44% of its $238M portfolio in Q1 2015.
- Iguana Healthcare Management opened 31 new positions and closed 28 in Q1 2015.
- Iguana Healthcare Management's portfolio value rose 15% quarter-over-quarter to $238M.
Based on Iguana Healthcare Management's 13F filing for Q1 2015, filed 18 May 2015.